Published in Volume 115, Issue 4
J. Clin. Invest.
115(4):
1100-1100 (2005).
doi:10.1172/JCI24282C1.
Copyright © 2005, The American Society for Clinical Investigation
Corrigendum
Liver fibrosis
Ramón Bataller and
David A. Brenner
Original citation: J. Clin. Invest.115:209–218(2005). doi:10.1172/JCI24282
Citation for this corrigendum: J. Clin. Invest.115:1100 (2005). doi:10.1172/JCI24282C1
PPARg agonists but not PPAR antagonists, as listed in Table 2, have shown inhibitory
effects on HSCs and antifibrotic effects in animal models with liver fibrosis and
patients with NASH.
The authors regret the error.
